Carvasept

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Carvasept is a medication used to treat hemorrhoids, anal fissures, and pruritus ani.

Generic Name
Carvasept
DrugBank Accession Number
DB15886
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 184.66
Monoisotopic: 184.0654927
Chemical Formula
C10H13ClO
Synonyms
  • Carvasept
  • Chlorcarvacrol
  • Chlorocarvacrol
  • MCIT

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to treatAnal fissuresCombination Product in combination with: Levomenthol (DB00825), Ichthammol (DB11341)••• •••••••••••
Used in combination to treatExternal hemorrhoidCombination Product in combination with: Levomenthol (DB00825), Ichthammol (DB11341)••• •••••••••••
Used in combination to treatHemorrhoids, internalCombination Product in combination with: Levomenthol (DB00825), Ichthammol (DB11341)••• •••••••••••
Used in combination to treatPruritus aniCombination Product in combination with: Ichthammol (DB11341), Levomenthol (DB00825)••• •••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Delta - Hädensa - ZäpfchenCarvasept (1 mg) + Ichthammol (4 mg) + Levomenthol (50 mg) + Prednisolone (1 mg)SuppositoryRectalMerz Pharma Austria Gmb H1969-12-10Not applicableAustria flag
Hädensa - SalbeCarvasept (0.05 g) + Ichthammol (0.5 g) + Levomenthol (2.5 g)OintmentTopicalMerz Pharma Austria Gmb H1938-11-12Not applicableAustria flag
Hädensa ZäpfchenCarvasept (1 mg) + Ichthammol (4 mg) + Levomenthol (50 mg)SuppositoryRectalMerz Pharma Austria Gmb H1959-09-10Not applicableAustria flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
5EL163606Q
CAS number
5665-94-1
InChI Key
AFFXNOIULZQAML-UHFFFAOYSA-N
InChI
InChI=1S/C10H13ClO/c1-6(2)8-5-10(12)7(3)4-9(8)11/h4-6,12H,1-3H3
IUPAC Name
4-chloro-2-methyl-5-(propan-2-yl)phenol
SMILES
CC(C)C1=C(Cl)C=C(C)C(O)=C1

References

General References
  1. BASG: Hädensa (Carvasept, Ichthammol, and Levomenthol) Topical Ointment [Link]
ChemSpider
20560
BindingDB
248168
ZINC
ZINC000000155367

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
OintmentTopical
SuppositoryRectal
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.123 mg/mLALOGPS
logP3.86ALOGPS
logP4.03Chemaxon
logS-3.2ALOGPS
pKa (Strongest Acidic)9.39Chemaxon
pKa (Strongest Basic)-6.3Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count1Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area20.23 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity52.08 m3·mol-1Chemaxon
Polarizability19.97 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0900000000-6cfb8bf3385662a8a822
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-9400000000-c8540608caf0a36326d3
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00ou-1900000000-b0bf1377c607b65988ef
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-f163696913fcf7bd37bf
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-34a3b80cb0a20fb8faf1
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0gz9-2900000000-540d558c5ebba9972bd8
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at September 25, 2020 21:45 / Updated at May 07, 2021 21:08